Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Irreversible Electroporation in Combination With Immune Checkpoint Inhibition, in Patients With Metastatic Pancreatic Cancer - A Prospective, Phase 2 Study

NCT05435053 is registered in ClinicalTrials.gov with Ismail Gögenur as lead sponsor.

NCT NCT05435053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05435053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Irreversible Electroporation in Combination With Immune Checkpoint Inhibition, in Patients With Metastatic Pancreatic Cancer - A Prospective, Phase 2 Study
Lead sponsor
Ismail Gögenur
Phase
Phase 2
Overall status
Terminated
Start date
September 8, 2022
Completion date
August 30, 2023
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer